Condition
Lung Cancer|Esophageal Cancer|Malignant Pleural Mesothelioma|Sarcoma|Thymic Carcinoma
Estimated Enrollment: 10
Age Group: 18 Years to 120 Years (Adult, Senior)
Gender: All
Study Type: Interventional
Study Design Allocation: Intervention Model: Single Group Assignment|Primary Purpose: Treatment
Study ID Numbers: 100138|10-C-0138
Study First Received: June 11, 2010
Last Updated: April 20, 2017
Estimated Primary Completion Date: February 9, 2015
Primary Outcome Measures:
Tabulation of toxicity type and grade|To ascertain if K526-GM vaccines induce immunity to CT antigens commonly expressed in thoracic malignancies.|To determine if metronomic oral CP and celecoxib reduce the number, percentage and function of CD4+ CD25+ Fox P3+ regulatory T cells (T reg) in peripheral blood of thoracic oncology patients.
Sponsors and Collaborators:
National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)
Website Link: https://ClinicalTrials.gov/show/NCT01143545
